NEUMOLOGÍA PEDIÁTRICA

Neumol Pediatr 2021; 16 (2): 62 - 68 Revista Neumología Pediátrica | Contenido disponible en www.neumologia-pediatrica.cl 68 Rol de la fracción espirada de óxido nítrico en el niño con diagnóstico de asma bronquial for Clinical Applications. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med. 201;184(5):602-15. doi: 10.1164/rccm.9120-11ST. PMID: 21885636; PMCID: PMC4408724. 18. Guo Z, Wang Y, Xing G, Wang X. Diagnostic accuracy of fractional exhaled nitric oxide in asthma: a systematic re- view and meta-analysis of prospective studies. J Asthma. 2016;53(4):404-12. doi: 10.3109/02770903.2015.1101132. Epub2016 Jan21. PMID: 26796787. 19. Tang S, Xie Y, Yuan C, Sun X, Cui Y. Fractional Exhaled Nitric Oxide for the Diagnosis of Childhood Asthma: a Systema- tic Review and Meta-analysis. Clin Rev Allergy Immunol. 2019;56(2):129-138. doi: 10.1007/s12016-016-8573-4. PMID: 27444490. 20. NICE Guideline Asthma: diagnosis, monitoring and chro- nic asthma. Available from https://www.nice.org.uk/ guidance/ng80/resources/asthma-diagnosis-moni- toring-and-chronic-asthma-management. (accesado marzo 2021) 21. Murray C, Foden P, Lowe L, Durrington H, Custovic A, Simpson A. Diagnosis of asthma in symptomatic chil- dren based on measures of lung function: an analysis of data from a population-based birth cohort study. Lan- cet Child Adolesc Health. 2017;1(2):114-123. doi: 10.1016/ S2352-4642(17)30008-1. PMID: 29034296; PMCID: PMC5616137. 22. Alving K. FeNO and suspected asthma: better to identify responsiveness to treatment than to label with a diagno- sis. Lancet Respir Med. 2018;6(1):3-5. doi: 10.1016/S2213- 2600(17)30429-0. Epub 2017 Nov 3. PMID: 29108939. 23. Dinh-Xuan A-T, Hall G. Developing Lung Function Initiative (GLI) reference equations for exhaled and nasal nitric oxide (TF-2018-07). Available from: https://www.ersnet.org/ research/task- forces. Date last accessed: November 8, 2019. 24. Moeller A, Diefenbacher C, Lehmann A, Rochat M, Brooks-Wildhaber J, Hall G, et al. Exhaled nitric oxide distinguishes between subgroups of preschool chil- dren with respiratory symptoms. J Allergy Clin Immu- nol 2008; 121:705– 9. PubMed:18177695. doi: 10.1016/j. jaci.2007.11.008 25. Castro-Rodriguez JA, Sardon O, Perez-Yarza EG, Korta J, Aldasoro A, Mintegui J, et al. Young infants with recurrent wheezing and positive asthma predictive index have higher levels of exhaled nitric oxide. J Asthma 2013; 50:162–5. doi: 10.3109/02770903.2012.754030 26. Oh MA, Shim JY, Jung YH, Seo JH, Young Kim H, Hong SJ, et al. Fraction of exhaled nitric oxide and wheezing phe- notypes in preschool children. Pediatr Pulmonol 2013; 48:563–70. doi: 10.1002/ppul.22705. 27. Singer F, Luchsinger I, Inci D, Knauer N, Latzin P, Wildhaber J, et al. Exhaled nitric oxide in symptomatic children at pres- chool age predicts later asthma. Allergy 2013; 68:531–8. doi: 10.1111/all.12127 28. PijnenburgMW.TheRoleof FeNO inPredictingAsthma. Front Pediatr. 2019 21;7:41. doi: 10.3389/fped.2019.00041. PMID: 30847334; PMCID: PMC6393362. 29. White MP, Kolstad TK, Elliott M, Cochrane ES, Stamey DC, Debley JS. Exhaled Nitric Oxide in Wheezy Infants Predicts Persistent AtopicAsthma andExacerbations at School Age. J Asthma Allergy. 2020;13:11-22. doi:10.2147/JAA.S227732 30. Linn WS, Rappaport EB, Berhane KT, Bastain TM, Avol EL, Gilliland FD. Exhaled nitric oxide in a population-based study of southern California schoolchildren. Respir Res. 2009;10(1):28. doi: 10.1186/1465-9921-10-28. PMID: 19379527; PMCID: PMC2678086. 31. Di Cara G, Marcucci F, Palomba A; Milioni M, Pecoraro L, Ciprandi G, et al. Exhaled nitric oxide in children with aller- gic rhinitis: A potential biomarker of asthma development. Pediatr Allergy Immunol. 2014;26(1):85-87. DOI: 10.1111/ pai.12326 32. Smith AD, Cowan JO, Brassett KP, Filsell S, McLachlan C, Monti-Sheehan G, et al. Exhaled nitric oxide: a pre- dictor of steroid response. Am J Respir Crit Care Med. 200;172(4):453-9. doi: 10.1164/rccm.200411-1498OC. Epub 2005May 18. PMID: 15901605. 33. Szefler SJ, Phillips BR, Martinez FD, Chinchilli VM, Lemans- ke RF, Strunk RC, et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. The Journal of allergy and clinical immunology. 2005;115(2):233-42. 30. 34. Ngo-Minh X, Tang-Thi-Thao T, Doan-Thi-Quynh N, Craig TJ, Duong-Quy S. Study of the role of exhaled nitric oxide (NO) in predicting controlled or uncontrolled asthma in as- thmatic children. Multidiscip Respir Med. 2020; 15(1):656. doi: 10.4081/mrm.2020.656. PMID: 32431811; PMCID: PMC7232017. 35. Heaney LG, Busby J, Bradding P, Chaudhuri R, Mansur AH, Niven R, et al. Medical Research Council UK Refractory As- thma Stratification Programme (RASP-UK). Remotely Mo- nitoredTherapy andNitricOxideSuppression IdentifiesNo- nadherence in Severe Asthma. Am J Respir Crit Care Med. 2019;199(4):454-464. doi: 10.1164/rccm.201806-1182OC. PMID: 30339770. 36. McNicholl DM, Stevenson M, McGarvey LP, Heaney LG. The utility of fractional exhaled nitric oxide suppression in the identification of nonadherence in difficult asthma. Am J Respir Crit Care Med. 2012;186(11):1102-8. doi: 10.1164/rcc- m.201204-0587OC. Epub 2012 Sep 28. PMID: 23024023. 37. Pijnenburg MW, Hofhuis W, Hop WC, De Jongste JC. Ex- haled nitric oxide predicts asthma relapse in children with clinical asthma remission. Thorax. 2005;60(3):215-8. doi: 10.1136/thx.2004.023374. PMID: 15741438; PMCID: PMC1747332. 38. Wang K, Verbakel JY, Oke J, Fleming-Nouri A, Harada N, Atsuta R, et al. Using fractional exhaled nitric oxide to gui- de step-down treatment decisions in asthma: practical considerations. Eur Respir J. 2020;56(2):2002809. doi: 10.1183/13993003.02809-2020. PMID: 32820024. 39. Menzies-Gow A, Mansur AH, Brightling CE. Clinical uti- lity of fractional exhaled nitric oxide in severe asthma management. Eur Respir J. 2020;55(3):1901633. doi: 10.1183/13993003.01633-2019. PMID: 31949116. 40. Dweik RA, Sorkness RL, Wenzel S, Hammel J, Cu- rran-Everett D, Comhair SA, et al. National Heart, Lung, and Blood Institute Severe Asthma Research Program. Use of exhaled nitric oxide measurement to identify a reactive, at-risk phenotype among patients with asth- ma. Am J Respir Crit Care Med. 2010;181(10):1033-41. doi: 10.1164/rccm.200905-0695OC. Epub 2010 Feb 4. PMID: 20133930; PMCID: PMC2874447. 41. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention 2020 Available from : ht- tps://ginasthma.org/wp-content/upload :/2020/06 (accesadomarzo 2021) 42. Casale TB, Luskin AT, Busse W, Zeiger RS, Trzaskoma B, Yang M, et al. Omalizumab Effectiveness by Biomarker Status in Patients with Asthma: Evidence From PROSPE- RO, AProspectiveReal-WorldStudy. J AllergyClin Immunol Pract. 2019;7(1):156-164.e1. doi: 10.1016/j.jaip.2018.04.043. Epub 2018May 22. PMID: 29800752. 43. Hanania NA, Wenzel S, Rosén K, Hsieh HJ, Mosesova S, Choy DF, et all. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med. 2013;187(8):804-11. doi: 10.1164/rccm.201208-1414OC. PMID: 2347146 44. Hanania NA, Korenblat P, Chapman KR, Bateman ED,Kopecky P,Paggiaro P, et al. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LA- VOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. The Lancet. Respi- ratory Medicine. 2016;4(10):781-796. DOI: 10.1016/s2213- 2600(16)30265-x. 45. Panettieri RA Jr, Sjöbring U, Péterffy A, Wessman P, Bowen K, Piper E, et al. Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials. Lancet Respir Med. 2018 ;6(7):511-525. doi: 10.1016/S2213- 2600(18)30184-X. Epub 2018May 20. PMID: 29792288. 46. CastroM, Corren J, Pavord ID, Maspero J,Wenzel S, RabeKF, et al. Dupilumab Efficacy and Safety inModerate-to-Seve- reUncontrolledAsthma. NEngl JMed. 2018;378(26):2486- 2496. doi: 10.1056/NEJMoa1804092. Epub 2018 May 21. PMID: 29782217. 47. Wenzel S. E., Pavord I., Zhang B., Maroni J., Rowe P., Hamil- ton J. D., et al. Type2biomarkers associatedwithdupilumab efficacy in patients with uncontrolled, moderate-to-severe asthma enrolled in the phase 3 study LIBERTY ASTHMA QUEST. 197. Am J Respir Crit CareMed 2018; 197: A9549. 48. Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012 ;380(9842):651-9. doi: 10.1016/S0140- 6736(12)60988-X. PMID: 22901886. 49. Haldar P, Brightling CE, Hargadon B, Gupta S, Montei- ro W, Sousa A, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009 ;360(10):973-84. doi: 10.1056/NEJMoa0808991. Erratum in: N Engl J Med. 2011;364(6):588. PMID: 19264686; PM- CID: PMC3992367. 50. Shrimanker R, Keene O, Hynes G, Wenzel S, Yancey S, Pa- vord ID. Prognostic andPredictiveValueof BloodEosinophil Count, Fractional Exhaled Nitric Oxide, and Their Combina- tion in Severe Asthma: A Post Hoc Analysis. Am J Respir Crit Care Med. 2019 ;200(10):1308-1312. doi: 10.1164/rcc- m.201903-0599LE. PMID: 31298922. 51. Van der Valk RJ, Baraldi E, Stern G, Frey U, de Jongste JC. Daily exhaled nitric oxide measurements and asthma exacerbations in children. Allergy. 2012 ;67(2):265-71. doi: 10.1111/j.1398-9995.2011.02734.x. Epub 2011 Oct 17. PMID: 21999328. 52. Fielding S, Pijnenburg M, De Jongste J, Pike G,Roberts G, Petsky H, Chang A, et al. What is a clinically meaningful change in exhaled nitric oxide for children with asth- ma? Pediatric Pulmonology. 2020 ;55(3):599-606. DOI: 10.1002/ppul.24630. 53. Petsky HL, Kew KM, Chang AB. Exhaled nitric oxide le- vels to guide treatment for children with asthma. Co- chrane Database Syst Rev. 2016 ;11(11):CD011439. doi: 10.1002/14651858.CD011439.pub2. PMID: 27825189; PMCID: PMC6432844. 54. Wang X, Tan X, Li Q. Effectiveness of fractional exhaled nitric oxide for asthma management in children: A sys- tematic review and meta-analysis. Pediatr Pulmonol. 2020;55(8):1936-1945. doi: 10.1002/ppul.24898. Epub 2020 Jun 22. PMID: 32525611. 55. Fielding SS, Pijnenburg M, de Jongste J, Pike K, Roberts G, Petsky H, et al. Does treatment guided by exhaled nitric oxide fraction improve outcomes in subgroups of chil- dren with asthma? Eur Respir J. 2020 ;55(5):1901879. doi: 10.1183/13993003.01879-2019. PMID: 32165403. 56. 2020 Focused Updates to the Asthma Management Gui- delines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. Available from : https://www.nhlbi . nih.gov/health-topics/all-publications and resources/ 2020-focused-updates-asthma-management-guideli- nes. Accessedmars 2021